Investor Relations - Curis

Month Year

Investor Alerts

Mar 19, 2020

Curis Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update

- Prioritizing resources for CA-4948 and CI-8993 clinical development programs -

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter...
Mar 12, 2020

Curis to Release Fourth Quarter and Year-End 2019 Financial Results and Hold Conference Call on March 19, 2020

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth...
Feb 27, 2020

Curis Announces $30 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into a common stock...
Feb 6, 2020

Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170

- Aurigene to fund and conduct a Phase 2b/3 randomized study of CA-170 in patients with non-squamous non-small cell lung cancer (nsNSCLC) -

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an amendment of its...
- Photos 1
Jan 13, 2020

Curis® and DarwinHealth Announce Scientific Collaboration to Characterize Biomarkers and Tumor Subtype Alignments for Fimepinostat in DLBCL and Solid Malignancies

Curis, Inc (NASDAQ: CRIS) and DarwinHealth, Inc. today announced a multi-year scientific research collaboration to use quantitative, systems biology-based algorithms, CLIA-approved technologies,...
- Photos 1
Jan 8, 2020

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 2, 2020, the independent...
Jan 7, 2020

Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies

- Curis to initiate Phase 1a/1b study for CI-8993 in 2020 -

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an option and...
Dec 6, 2019

Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study

- Preliminary clinical data on CA-4948 demonstrates anti-cancer activity and favorable safety profile -

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced updated preliminary data from its ongoing...
Dec 6, 2019

Curis Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax

- 11 patients enrolled to-date in Phase 1 study; combination has been generally well-tolerated -

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced preliminary tolerability and PK data from its...
Nov 26, 2019

Curis to Present at 31st Annual Piper Jaffray Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, Chief Executive Officer...

Show per page